BASEL (dpa-AFX) - Cigna (CI) announced it has entered into an outcomes-based contract with Novartis for Entresto, which was approved by the U.S. FDA for the treatment of heart failure with reduced ejection fraction. The agreement is effective for Cigna's commercial business.
Cigna noted that the pay-for-performance agreement ties the financial terms to how well the drug improves the relative health of Cigna's customers.
Copyright RTT News/dpa-AFX